Cyclacel And ALTANA Pharma AG (AAA) Announce Collaboration On Mitotic Target Identification
10/19/2005 5:13:01 PM
DUNDEE, Scotland & KONSTANZ, Germany--(BUSINESS WIRE)--March 16, 2005--Cyclacel Group plc ("Cyclacel"), the cell cycle-based biopharmaceutical company, announced today execution of a research collaboration agreement with ALTANA Pharma AG, the pharmaceutical division of ALTANA AG (NYSE:AAA)(FWB:ALT), in which Cyclacel will use its expertise in mitosis or cell division to identify the molecular targets of specific ALTANA Pharma experimental drugs.
Under the terms of the agreement ALTANA Pharma will supply Cyclacel with selected experimental molecules shown to interfere with mitosis. Scientists at Cyclacel's Polgen Division in Cambridge, UK, where the work will be undertaken, will apply their knowledge of mitosis biology combined with Cyclacel's Drosophila RNA interference library to identify the targets of the ALTANA Pharma molecules. Knowledge of the drug targets will enable ALTANA Pharma to accelerate the development of drug candidates. Financial terms of the agreement were not disclosed.
comments powered by